|
POU5F1P4
|
Malignant Neoplasms
|
0.100 |
Biomarker |
BEFREE |
Cancer stem cells were analyzed using the marker Oct-4 to improve an understanding of the proliferative ability of cancer stem cells under various pathological conditions, which may lead to the development of novel cancer therapeutics.
|
29142598 |
2017 |
|
POU5F1P4
|
Malignant Neoplasms
|
0.100 |
AlteredExpression |
BEFREE |
Using real-time polymerase chain reaction (PCR), Western blotting, immunocytochemistry and immunohistochemistry, the expression of OCT4 in three esophageal squamous cancer cell lines, KYSE70, KYSE140 and KYSE450, was characterized.
|
22363145 |
2012 |
|
POU5F1P4
|
Malignant Neoplasms
|
0.100 |
AlteredExpression |
BEFREE |
TAZ knockdown results in inhibition of cancer cell proliferation through decreases in expression of stem cell markers (OCT4, Nanog, and SOX2).
|
25495189 |
2015 |
|
POU5F1P4
|
Malignant Neoplasms
|
0.100 |
AlteredExpression |
BEFREE |
Although Oct-3/4 expression has been implicated in the malignancy and prognosis of glioblastomas, little is known of its involvement in drug resistances of glioblastoma.
|
25644290 |
2015 |
|
POU5F1P4
|
Malignant Neoplasms
|
0.100 |
AlteredExpression |
BEFREE |
In HCC-derived cells, SRY knockdown decreased OCT4 expression and cancer stem-like phenotypes such as self-renewal, chemoresistance, and tumorigenicity.
|
26013162 |
2015 |
|
POU5F1P4
|
Malignant Neoplasms
|
0.100 |
Biomarker |
BEFREE |
Furthermore, treatment of HB cells with aprepitant led to reduced expression of (liver) stemness markers (AFP, CD13, SOX2, NANOG, and OCT4) and SFA when grown under cancer stem cell conditions.
|
26516161 |
2015 |
|
POU5F1P4
|
Malignant Neoplasms
|
0.100 |
AlteredExpression |
BEFREE |
Using OCT4 expression as a marker for the cancer stem cells, the number and size were measured in these cells.
|
22132214 |
2011 |
|
POU5F1P4
|
Malignant Neoplasms
|
0.100 |
AlteredExpression |
BEFREE |
<i>NANOG</i> and <i>OCT3/4</i> mRNA expression levels were significantly downregulated while that of <i>SOX2</i> was upregulated in cancer compared to noncancer tissues.
|
29849920 |
2018 |
|
POU5F1P4
|
Malignant Neoplasms
|
0.100 |
AlteredExpression |
BEFREE |
Overall, an association between expression of OCT4 and pseudogenes and cancer prognosis were established, which may serve as a therapeutic target for various human cancers.
|
30287838 |
2018 |
|
POU5F1P4
|
Malignant Neoplasms
|
0.100 |
Biomarker |
BEFREE |
The present data shows that Oct4 enhances cancer stem cell properties and increases invasion ability in the Huh7 cell line.
|
28454439 |
2017 |
|
POU5F1P4
|
Malignant Neoplasms
|
0.100 |
Biomarker |
BEFREE |
Coexpression of Oct4 and Nanog enhances malignancy in lung adenocarcinoma by inducing cancer stem cell-like properties and epithelial-mesenchymal transdifferentiation.
|
21159654 |
2010 |
|
POU5F1P4
|
Malignant Neoplasms
|
0.100 |
Biomarker |
BEFREE |
The generation of induced pluripotent stem cells (iPSCs) from somatic cells by expressing ectopic reprogramming transcriptional factors such as Oct3/4, Sox2, Klf4, c-Myc, and Nanog is one of the cutting-edge discoveries in stem cell and cancer research.
|
24568610 |
2014 |
|
POU5F1P4
|
Malignant Neoplasms
|
0.100 |
Biomarker |
BEFREE |
The positive-feedback regulation via OCT4-mediated transactivation of the c-JUN promoter and the c-JUN-mediated transactivation of the OCT4 promoter were crucial for promoting cancer development and maintaining cancer stemness in rG2-DC-1C.
|
27341307 |
2016 |
|
POU5F1P4
|
Malignant Neoplasms
|
0.100 |
Biomarker |
BEFREE |
The results suggest that transplantation of such in vitro enriched and expanded OCT4-specific CD8+ CIK cells may improve the specific immune defense mechanism against cancer stem cells, providing a novel avenue of cancer stem cell targeted immunotherapy for clinical treatment of ovarian cancer.
|
28426690 |
2017 |
|
POU5F1P4
|
Malignant Neoplasms
|
0.100 |
AlteredExpression |
BEFREE |
In this study, we aimed to characterize the ID4 expression pattern in human diffusely infiltrative astrocytomas of World Health Organization (WHO) grades II to IV of malignancy (AGII-AGIV); to correlate its expression level to that of SOX2, SOX4, OCT-4 and NANOG, along with TP53 mutational status; and to correlate the results with the clinical end-point of overall survival among glioblastoma patients.
|
23613880 |
2013 |
|
POU5F1P4
|
Malignant Neoplasms
|
0.100 |
AlteredExpression |
BEFREE |
Oct4 is expressed by CSC-like cells in different types of cancer.
|
22286766 |
2012 |
|
POU5F1P4
|
Malignant Neoplasms
|
0.100 |
AlteredExpression |
BEFREE |
Moreover, TGFβ1 was able to enhance the mRNA expression of Oct4, Nanog and Sox2 and drastically increased anchorage-independent colony formation in TGFβ1-sensitive NSCLC cells, suggesting the acquisition of cancer stem-like properties.
|
29995950 |
2018 |
|
POU5F1P4
|
Malignant Neoplasms
|
0.100 |
Biomarker |
BEFREE |
Oct4 promotes cancer cell proliferation and migration and leads to poor prognosis associated with the survivin/STAT3 pathway in hepatocellular carcinoma.
|
29901157 |
2018 |
|
POU5F1P4
|
Malignant Neoplasms
|
0.100 |
Biomarker |
BEFREE |
Global Oct4 target gene analysis reveals novel downstream PTEN and TNC genes required for drug-resistance and metastasis in lung cancer.
|
25609695 |
2015 |
|
POU5F1P4
|
Malignant Neoplasms
|
0.100 |
Biomarker |
BEFREE |
The BORIS-positive cells isolated using BORIS-molecular beacon, expressed higher telomerase hTERT, stem cell (NANOG, OCT4, SOX2) and cancer stem cell marker genes (CD44 and ALDH1) compared to the BORIS-negative tumor cells.
|
25279549 |
2014 |
|
POU5F1P4
|
Malignant Neoplasms
|
0.100 |
AlteredExpression |
BEFREE |
Re-expression of OCT4 enhanced the expression of Notch, Sox2 and Nanog molecules that play critical roles in cancer stem cell proliferation and differentiation.
|
23921511 |
2013 |
|
POU5F1P4
|
Malignant Neoplasms
|
0.100 |
Biomarker |
BEFREE |
Treatment of tumor-bearing mice with genotoxic chemotherapy not only prolonged survival and reduced tumor size but also selectively eliminated the OCT4-positive cancer stem cells.
|
29141221 |
2017 |
|
POU5F1P4
|
Malignant Neoplasms
|
0.100 |
GeneticVariation |
BEFREE |
Also, mRNA expression of transcriptional marker Nanog and Octamer-binding transcription factor 4 (OCT4), known to enhance malignancy and metastasis in lung adenocarcinoma, was suppressed in ZNF746 siRNA-transfected H460 NSCLC cells.
|
24145959 |
2014 |
|
POU5F1P4
|
Malignant Neoplasms
|
0.100 |
AlteredExpression |
BEFREE |
Although differentially displayed, the expression of genes related to cancer (BCL-2, p53, NF-κB, TGF-β, VEGF) and transcription and pluripotency (OCT4, NANOG, STAT3, REX1) were commonly observed in MSCs and cancer cells.
|
21638208 |
2011 |
|
POU5F1P4
|
Malignant Neoplasms
|
0.100 |
AlteredExpression |
BEFREE |
Both HOXA11-AS silencing and HOXA11 overexpression suppressed the self-renewal, proliferation, migration, and tumorigenicity of HCC stem cells in vivo, as evidenced by the decreased expression of cancer stem cell surface markers (CD133 and CD44) and stemness-related transcription factors (Nanog, Sox2, and Oct4).
|
31757938 |
2019 |